Search
Benzathine penicillin G (BPG) is used as first-line treatment for most forms of syphilis and as secondary prophylaxis against rheumatic heart disease (RHD). Perceptions that poor quality of BPG is linked to reported adverse effects and therapeutic failure may impact syphilis and RHD control programs. Clinical networks and web-based advertising were used to obtain vials of BPG from a wide range of countries.
This systematic review presents a critical, interpretive analysis of publications that include lived experiences of rheumatic heart disease
Australia needs a single national pharyngitis guideline to assist in providing rational, consistent and timely antibiotic treatment to patients at high risk of ARF
Efforts to eliminate ARF and RHD in Australia over the past decade have so far been unsuccessful, but this can change
These results indicate that anaphylaxis is not a major cause of adverse reactions to benzathine penicillin G
The ERASE Project has created an unprecedented linked administrative database on acute rheumatic fever and rheumatic heart disease in Australia
The current prophylactic treatment to prevent rheumatic heart disease requires four-weekly intramuscular injection of a suspension of the poorly soluble benzathine salt form of penicillin G (BPG) often for more than 10 years. In seeking to reduce the frequency of administration to improve adherence, biodegradable polymer matrices have been investigated.
Rheumatic heart disease (RHD) is a chronic cardiac condition with an infectious aetiology, causing high disease burden in low-income settings.
The choice of RHD is telling: the disease is a marker of inequality, a novel lens for considering health systems and a feasible target for disease control.
Over the last decade, a massive increase in data collection and analysis has occurred in many fields.